APLS
Apellis Pharmaceuticals Inc
3.40$
-0.1%
vs. previous close
Closing price · As of: Aug 13, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | -43.2% | -375.9% | – | +2,340.2% | -113.1% | – | – | |
| – | -1.2% | +21.0% | -9.4% | +1.1% | +1.8% | -2.2% | -0.2% | +0.0% | -24.0% | -463.1% | – | – | |
| – | -26.1% | +21.2% | +15.8% | -1.2% | -8.4% | -4.2% | +4.0% | -0.6% | +3.6% | -393.6% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | -54.8% | -63.3% | +76.3% | -843.8% | – | -569.0% | – | |
| – | -87.4% | +102.1% | +208.4% | -69.3% | -100.0% | – | -60.0% | +512.5% | +202.0% | +38.5% | -100.0% | – | |
| – | -87.4% | – | -7,425.0% | -69.3% | – | – | -60.0% | +512.5% | +202.0% | -27.0% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -60.7% | -81.8% | +1,300.0% | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +268.3% | -168.1% | – | -60.7% | -94.0% | -257.4% | – | +2,293.4% | -87.9% | +58.8% | -94.9% | – | |
| – | – | – | – | – | +7.0% | -60.9% | -467.2% | – | +837.7% | -111.8% | – | – | |
| – | – | – | – | – | – | -43.3% | -376.2% | – | +2,364.1% | -112.9% | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: August 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.